Overview

Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis

Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the efficacy of 611 in Chinese Adolescents with moderate to severe atopic dermatitis.
Phase:
PHASE3
Details
Lead Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Treatments:
entacapone